Alexandra MacLean, Avenue Therapeutics CEO
April 18, 2023 11:05 AM EDT
FDA+

Av­enue touts progress with FDA on em­bat­tled pain can­di­date af­ter two CRLs, failed ad­comm

Paul Schloesser

Associate Editor

Av­enue Ther­a­peu­tics says it is most­ly in agree­ment with FDA on tri­al pro­to­cols for a po­ten­tial Phase III safe­ty study, which could lead to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times